Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.
There is limited data on the clinical, cellular and molecular changes in relapsed acute promyeloytic leukemia (RAPL) in comparison with newly diagnosed cases (NAPL). We undertook a prospective study to compare NAPL and RAPL patients treated with arsenic trioxide (ATO) based regimens. 98 NAPL and 28...
Main Authors: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4378855?pdf=render |
id |
doaj-df7684acf6474b0e8b346f8d42ae963e |
---|---|
record_format |
Article |
spelling |
doaj-df7684acf6474b0e8b346f8d42ae963e2020-11-25T01:30:48ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e012191210.1371/journal.pone.0121912Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance.Ezhilarasi ChendamaraiSaravanan GanesanAnsu Abu AlexVandana KamathSukesh C NairArun Jose NellickalNancy Beryl JanetVivi SrivastavaKavitha M LakshmiAuro ViswabandyaAby AbrahamMohammed AiyazNandita MullapudiRaja MugasimangalamRose Ann PaduaChristine ChomienneMammen ChandyAlok SrivastavaBiju GeorgePoonkuzhali BalasubramanianVikram MathewsThere is limited data on the clinical, cellular and molecular changes in relapsed acute promyeloytic leukemia (RAPL) in comparison with newly diagnosed cases (NAPL). We undertook a prospective study to compare NAPL and RAPL patients treated with arsenic trioxide (ATO) based regimens. 98 NAPL and 28 RAPL were enrolled in this study. RAPL patients had a significantly lower WBC count and higher platelet count at diagnosis. IC bleeds was significantly lower in RAPL cases (P=0.022). The ability of malignant promyelocytes to concentrate ATO intracellularly and their in-vitro IC50 to ATO was not significantly different between the two groups. Targeted NGS revealed PML B2 domain mutations in 4 (15.38%) of the RAPL subset and none were associated with secondary resistance to ATO. A microarray GEP revealed 1744 genes were 2 fold and above differentially expressed between the two groups. The most prominent differentially regulated pathways were cell adhesion (n=92), cell survival (n=50), immune regulation (n=74) and stem cell regulation (n=51). Consistent with the GEP data, immunophenotyping revealed significantly increased CD34 expression (P=0.001) in RAPL cases and there was in-vitro evidence of significant microenvironment mediated innate resistance (EM-DR) to ATO. Resistance and relapse following treatment with ATO is probably multi-factorial, mutations in PML B2 domain while seen only in RAPL may not be the major clinically relevant cause of subsequent relapses. In RAPL additional factors such as expansion of the leukemia initiating compartment along with EM-DR may contribute significantly to relapse following treatment with ATO based regimens.http://europepmc.org/articles/PMC4378855?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ezhilarasi Chendamarai Saravanan Ganesan Ansu Abu Alex Vandana Kamath Sukesh C Nair Arun Jose Nellickal Nancy Beryl Janet Vivi Srivastava Kavitha M Lakshmi Auro Viswabandya Aby Abraham Mohammed Aiyaz Nandita Mullapudi Raja Mugasimangalam Rose Ann Padua Christine Chomienne Mammen Chandy Alok Srivastava Biju George Poonkuzhali Balasubramanian Vikram Mathews |
spellingShingle |
Ezhilarasi Chendamarai Saravanan Ganesan Ansu Abu Alex Vandana Kamath Sukesh C Nair Arun Jose Nellickal Nancy Beryl Janet Vivi Srivastava Kavitha M Lakshmi Auro Viswabandya Aby Abraham Mohammed Aiyaz Nandita Mullapudi Raja Mugasimangalam Rose Ann Padua Christine Chomienne Mammen Chandy Alok Srivastava Biju George Poonkuzhali Balasubramanian Vikram Mathews Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. PLoS ONE |
author_facet |
Ezhilarasi Chendamarai Saravanan Ganesan Ansu Abu Alex Vandana Kamath Sukesh C Nair Arun Jose Nellickal Nancy Beryl Janet Vivi Srivastava Kavitha M Lakshmi Auro Viswabandya Aby Abraham Mohammed Aiyaz Nandita Mullapudi Raja Mugasimangalam Rose Ann Padua Christine Chomienne Mammen Chandy Alok Srivastava Biju George Poonkuzhali Balasubramanian Vikram Mathews |
author_sort |
Ezhilarasi Chendamarai |
title |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. |
title_short |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. |
title_full |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. |
title_fullStr |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. |
title_full_unstemmed |
Comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. |
title_sort |
comparison of newly diagnosed and relapsed patients with acute promyelocytic leukemia treated with arsenic trioxide: insight into mechanisms of resistance. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2015-01-01 |
description |
There is limited data on the clinical, cellular and molecular changes in relapsed acute promyeloytic leukemia (RAPL) in comparison with newly diagnosed cases (NAPL). We undertook a prospective study to compare NAPL and RAPL patients treated with arsenic trioxide (ATO) based regimens. 98 NAPL and 28 RAPL were enrolled in this study. RAPL patients had a significantly lower WBC count and higher platelet count at diagnosis. IC bleeds was significantly lower in RAPL cases (P=0.022). The ability of malignant promyelocytes to concentrate ATO intracellularly and their in-vitro IC50 to ATO was not significantly different between the two groups. Targeted NGS revealed PML B2 domain mutations in 4 (15.38%) of the RAPL subset and none were associated with secondary resistance to ATO. A microarray GEP revealed 1744 genes were 2 fold and above differentially expressed between the two groups. The most prominent differentially regulated pathways were cell adhesion (n=92), cell survival (n=50), immune regulation (n=74) and stem cell regulation (n=51). Consistent with the GEP data, immunophenotyping revealed significantly increased CD34 expression (P=0.001) in RAPL cases and there was in-vitro evidence of significant microenvironment mediated innate resistance (EM-DR) to ATO. Resistance and relapse following treatment with ATO is probably multi-factorial, mutations in PML B2 domain while seen only in RAPL may not be the major clinically relevant cause of subsequent relapses. In RAPL additional factors such as expansion of the leukemia initiating compartment along with EM-DR may contribute significantly to relapse following treatment with ATO based regimens. |
url |
http://europepmc.org/articles/PMC4378855?pdf=render |
work_keys_str_mv |
AT ezhilarasichendamarai comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT saravananganesan comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT ansuabualex comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT vandanakamath comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT sukeshcnair comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT arunjosenellickal comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT nancyberyljanet comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT vivisrivastava comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT kavithamlakshmi comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT auroviswabandya comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT abyabraham comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT mohammedaiyaz comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT nanditamullapudi comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT rajamugasimangalam comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT roseannpadua comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT christinechomienne comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT mammenchandy comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT aloksrivastava comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT bijugeorge comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT poonkuzhalibalasubramanian comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance AT vikrammathews comparisonofnewlydiagnosedandrelapsedpatientswithacutepromyelocyticleukemiatreatedwitharsenictrioxideinsightintomechanismsofresistance |
_version_ |
1725089792739246080 |